Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: LY3502970, LY-3502970
Orforglipron, also known as LY3502970, is a nonpeptide small-molecule agonist that binds to and activates the human GLP-1 receptor. Reported pharmacodynamic effects include reduced food intake, appetite-mediated body-weight reduction, and delayed gastric emptying. The U.S. FDA approved orforglipron as the active ingredient in Foundayo on April 1, 2026.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
FDA labeling reports maximum plasma concentration at approximately 4 to 8 hours post-dose, greater than 99% plasma-protein binding, metabolism primarily by hepatic CYP3A4, and predominantly fecal recovery of administered material. These pharmacokinetic observations refer to the labeled orforglipron product and associated clinical formulations.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN: 2212020-52-3; PubChem CID: 137319706; Molecular formula: C48H48F2N10O5; Molecular weight: 883.0 g/mol; InChIKey: USUWIEBBBWHKNI-KHIFEHGGSA-N; FDA UNII: 7ZW40D021M; ChEMBL: CHEMBL4446782
The FDA-approved tablet formulation contains orforglipron calcium, whereas the PubChem parent-compound record reports free orforglipron. Orforglipron is classified by the developer as a small molecule and is described as an oral GLP-1 receptor agonist.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Orforglipron or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.